CO2019005207A2 - Medicinal complex to treat type 2 diabetes and diabetic dyslipidemia - Google Patents

Medicinal complex to treat type 2 diabetes and diabetic dyslipidemia

Info

Publication number
CO2019005207A2
CO2019005207A2 CONC2019/0005207A CO2019005207A CO2019005207A2 CO 2019005207 A2 CO2019005207 A2 CO 2019005207A2 CO 2019005207 A CO2019005207 A CO 2019005207A CO 2019005207 A2 CO2019005207 A2 CO 2019005207A2
Authority
CO
Colombia
Prior art keywords
diabetes
medicinal complex
treat type
diabetic dyslipidemia
medicinal
Prior art date
Application number
CONC2019/0005207A
Other languages
Spanish (es)
Inventor
Ki Sook Park
Hye Jin Yoon
Jong Hyuk Jung
Sung Won Kim
Ji Yoon Kim
Seok Cheol Yoo
Ri Sun Kim
Jae Soon Ahn
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019005207(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CO2019005207A2 publication Critical patent/CO2019005207A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

RESUMEN DE LA INVENCIÓN La presente invención se relaciona a un complejo medicinal para tratar efectivamente diabetes tipo 2 y dislipidemia de pacientes diabéticos, más específicamente, la presente invención proporciona un complejo medicinal que comprende un inhibidor de peptidasa IV, gemigliptin o una sal farmacéuticamente aceptable del mismo, y un inhibidor de HMG-CoA reductasa, rosuvastatina o una sal farmacéuticamente aceptable del mismo, para controlar efectivamente los niveles de azúcar en la sangre y mejorar factores de riesgo de la enfermedad cardiovascular.SUMMARY OF THE INVENTION The present invention relates to a medicinal complex for effectively treating type 2 diabetes and dyslipidemia of diabetic patients, more specifically, the present invention provides a medicinal complex comprising a peptidase IV inhibitor, gemigliptin or a pharmaceutically acceptable salt of the same, and an HMG-CoA reductase inhibitor, rosuvastatin or a pharmaceutically acceptable salt thereof, to effectively control blood sugar levels and improve risk factors for cardiovascular disease.

CONC2019/0005207A 2016-11-15 2019-05-22 Medicinal complex to treat type 2 diabetes and diabetic dyslipidemia CO2019005207A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160152195 2016-11-15
PCT/KR2017/012941 WO2018093144A1 (en) 2016-11-15 2017-11-15 Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia

Publications (1)

Publication Number Publication Date
CO2019005207A2 true CO2019005207A2 (en) 2019-08-20

Family

ID=62146049

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0005207A CO2019005207A2 (en) 2016-11-15 2019-05-22 Medicinal complex to treat type 2 diabetes and diabetic dyslipidemia

Country Status (9)

Country Link
KR (1) KR102055894B1 (en)
CN (1) CN109996545A (en)
BR (1) BR112019009709A2 (en)
CO (1) CO2019005207A2 (en)
MX (1) MX2019005572A (en)
PE (1) PE20191502A1 (en)
PH (1) PH12019501028A1 (en)
RU (1) RU2721406C1 (en)
WO (1) WO2018093144A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
ZA200708179B (en) * 2005-04-22 2009-12-30 Alantos Pharmaceuticals Holding Inc Dipeptidyl peptidase-IV inhibitors
AU2010281913A1 (en) * 2009-08-13 2012-04-05 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
BR112012012641A2 (en) * 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-lVTAL INHIBITORS LIKE LINAGLIPTIN
EP2566465A2 (en) * 2010-05-04 2013-03-13 Mahmut Bilgic Stable rosuvastatin formulations
KR20140013436A (en) * 2012-07-24 2014-02-05 한미약품 주식회사 Composite formulation for oral administration comprising metformin and rosuvastatin
TWI606848B (en) * 2012-10-08 2017-12-01 Ｌｇ生命科學股份有限公司 Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
TW201513857A (en) * 2013-07-05 2015-04-16 Cadila Healthcare Ltd Synergistic compositions
CN103494788B (en) * 2013-10-10 2015-08-05 齐晓彤 Pharmaceutical composition of rosuvastatin calcium tablets and preparation method thereof
CN104473929B (en) * 2014-12-17 2018-05-29 深圳翰宇药业股份有限公司 A kind of Xi Gelieting simvastatin slow-releases composition

Also Published As

Publication number Publication date
PH12019501028A1 (en) 2020-01-20
PE20191502A1 (en) 2019-10-22
CN109996545A (en) 2019-07-09
BR112019009709A2 (en) 2019-08-13
MX2019005572A (en) 2019-08-14
WO2018093144A1 (en) 2018-05-24
KR20180054500A (en) 2018-05-24
KR102055894B1 (en) 2019-12-13
RU2721406C1 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
CL2023002682A1 (en) Using ehmt2 inhibitors to treat blood disorders
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
EA201691320A1 (en) METHODS OF TREATMENT OF PATIENTS WITH HYPERSHOLESTERINEMIA, WHICH STABLE TO THERAPY WITH MODERN STATIN DOSES THERAPY
CO2017011197A2 (en) Combination therapy fgfr / pd-1 for cancer treatment
MX2022013172A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia.
CO2017004715A2 (en) Methods and formulations to treat vascular eye diseases
MX2021000898A (en) METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH).
BR112015009948A8 (en) Activin-actrii antagonists, uses thereof for treating bone diseases and other disorders, and method for monitoring the effectiveness of treating or preventing a bone disease and other disorders
CL2015002608A1 (en) Amino-pyrazole compound and related medicinal uses.
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
MX2021000289A (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia.
BR112015026021A2 (en) combination therapy comprising a tor kinase inhibitor and n- (3- (5-fluoro-2- (4- (2-methoxyethoxy) phenylamino) pyrimidin-4-ylamino) phenyl) acrylamide for cancer treatment
BR112018007026A2 (en) compound, gaba-at activity modulation method, dopamine level modulation method, substance dependence treatment method, ornithine aminotransferase activity modulation method, ornithine aminotransferase activity reduction method expressed by a human hepatocellular carcinoma and method for treating psychological and neurological disorders
CL2019001214A1 (en) Pharmaceutical composition, methods for treatment and their uses.
EA201890891A1 (en) BIOMARKERS ASSOCIATED WITH INTERLEYKIN-33 DISEASES, AND THEIR APPLICATION
CL2017001756A1 (en) Dosing regimen for madcam antagonists.
AR092899A1 (en) USE OF MASITINIB FOR THE TREATMENT OF CANCER IN SUB-POPULATIONS OF IDENTIFIED PATIENTS USING PREDICTION FACTORS
CO2017001899A2 (en) Cancer treatment with alpha-amylase inhibitor in companion animals
CL2021001623A1 (en) Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in treating cancer
MX2020003243A (en) Methods of treating heart failure with preserved ejection fraction.
CO2019005207A2 (en) Medicinal complex to treat type 2 diabetes and diabetic dyslipidemia
EA202091653A1 (en) MINOCYCLINE FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES
BR112014032264A8 (en) Composition for the treatment or prevention of diseases related to vascular permeability, containing imatinib or a pharmaceutically acceptable salt thereof as an active ingredient
CY1123322T1 (en) PHARMACEUTICAL COMPOSITION INCLUDING BISOPROLOL AND PERINDROPRIL
DOP2014000258A (en) TREATMENT OF THE METALASIS IN THE BRAIN WITH A COMBINATION OF VELIPARIB AND A THERAPY WITH RADIATION IN THE TOTALITY OF THE BRAIN